Conjunctival inflammation in the chronic phase of Stevens–Johnson syndrome

Satoshi Kawasaki, Kohji Nishida, Chie Sotozono, Andrew J Quantock, Shigeru Kinoshita

Abstract

**Aims**—To understand the immunopathogenesis of the corneal conjunctivalisation in Stevens–Johnson syndrome.

**Methods**—Conjunctivalised corneas from five patients with Stevens–Johnson syndrome were studied immunohistochemically for several cell surface antigens and two cytokines. Chemical injury specimens were also studied.

**Results**—In all cases, immunohistochemistry revealed LFA-1, CD4, CD8, and CD68 on subepithelial infiltrating cells. Also, HLA-DR and ICAM-1 were found on the surfaces of epithelial cells, subepithelial infiltrating cells, subepithelial fibrinoids, and endothelial cells in blood vessels. IFN-γ was found in basal epithelial cells; subepithelial cells and subepithelial extracellular matrix CD19 and IL4 were not detected.

**Conclusions**—The infiltrating cell population in the Stevens–Johnson syndrome samples includes macrophages, CD4 positive T cells, and CD8 positive T cells. The cytokine expression pattern suggests CD4 positive T cells are Th1 cells. The infiltrating cell population is similar in Stevens–Johnson syndrome and chemical injury conjunctivalised corneas.


Stevens–Johnson syndrome is an acute inflammatory disease that predominantly affects skin and mucosal membranes including the ocular surface. In the acute phase, ocular manifestations include corneal ulceration and severe pseudomembranous conjunctivitis. After the initial attack has passed, about half of the patients with severe systemic Stevens–Johnson syndrome continue to have ocular surface problems that include symblepharon, entropion, ectropion, trichiasis, dry eye, persistent conjunctival inflammation, conjunctival injection, and corneal opacification.

It is thought that the pathogenesis of Stevens–Johnson syndrome in the acute phase might be related to an immunological hypersensitivity to drugs or micro-organisms. However, little is known about the persistent inflammation during chronic phase Stevens–Johnson syndrome. To better understand the immunopathogenesis of the corneal conjunctivalisation that is seen in Stevens–Johnson syndrome, we examined tissue from five patients with Stevens–Johnson syndrome who presented at Kyoto Prefectural University of Medicine Hospital between March and July 1995. We similarly examined conjunctivalised corneas from three chemically injured eyes.

**Materials and methods**

Resected tissues specimens were frozen sectioned (6 µm thick) and placed on glass slides. Immunohistochemical studies were performed by the standard ABC method. Cold acetone was used as fixative for the detection of LFA-1, CD4, CD8, CD19, CD68, HLA-DR, and ICAM-1 and 4% paraformaldehyde was used as fixative for the detection of IFN-γ and IL-4.

To eliminate non-specific immune staining, 5% normal goat serum was used. All specimens were incubated overnight with the following primary antibodies at 4°C at the stated dilution (all were raised in mouse and purchased from Dako Corp (Glostrup, Denmark)): LFA-1 (1:200), CD4 (1:20), CD8 (1:200), CD19 (1:100), CD68 (1:100), HLA-DR (1:100), ICAM-1 (1:50). Anti-human IFN-γ (50 mg/ml) was purchased from Endogen (Cambridge, MA, USA) and the anti-human IL-4 (5 mg/ml) from Genzyme (Cambridge, MA, USA). For negative controls, normal mouse IgG was used instead of the primary antibody.

**Results and discussion**

Before surgery, no inflammation was noted in patients 2 and 5, whereas patients 1, 3, and 4 occasionally presented with mild inflammation. However, these mild inflammatory episodes invariably resolved without the administration of extra medication.

On histological examination, conjunctivalised corneas from all patients with Stevens–Johnson syndrome were characterised by fairly...
extensive subepithelial mononuclear infiltration (Fig 1A). No polymorphonuclear cells (PMNs) were evident in any regions of the specimens except for the vascular lumen. The conjunctivalised corneal epithelium was clearly thicker than normal in four of the five cases. All specimens showed positive immunohistochemical reactions for anti-LFA-1 (Fig 1B), anti-CD4 (Fig 1C), anti-CD8 (Fig 1D), anti-CD68 (Fig 1F), anti-HLA-DR (Fig 1G), and anti-ICAM-1 (Fig 1H). HLA-DR and ICAM-1 immunoreactivities were detected on subepithelial infiltrating cells, epithelial cells and endothelial cells of blood vessels. LFA-1, CD4, CD8, and CD68 immunoreactivities were detected on subepithelial mononuclear infiltrating cells only. However, CD19 immunoreactivity was not detected in any of the patients (Fig 1E). IFN-γ immunoreactivity was detected in subepithelial infiltrating cells, in the basal layer of the conjunctivalised corneal epithelium, and in endothelial cells of blood vessels (Fig 1I). IL-4 immunoreactivity was not evident except for on PMNs in the blood vessel (Fig 1J). Immunohistochemistry of conjunctivalised corneas from three chemically injured eyes (not shown) disclosed a similar pattern of cell surface antigen and cytokine immunoreactivity as did the conjunctivalised Stevens–Johnson syndrome corneas.

Stevens–Johnson syndrome is a self limited disease and many investigations have been done to elucidate the immunological mechanism of initial attack. Clinically, however,

Figure 1  Representative serial sections from Stevens–Johnson conjunctiva (patient No 4). Immunohistochemical sections are stained by the ABC method with DAB (counterstained with methyl green). (A) Haematoxylin and eosin (HE). Conjunctivalised corneal epithelium moderately thickened and subepithelial infiltrating cells notable. (B) Anti-LFA-1. Many immunopositive cells seen in the substantia propria of the conjunctiva. (C) Anti-CD4. Immunopositive cells seen in the substantia propria of the conjunctiva. (D) Anti-CD8. Immunopositive cells seen in the substantia propria of the conjunctiva. (E) Anti-CD19. No positive staining is seen in this section except for some polymorphonuclear cells in the vascular lumen. (F) Anti-CD68. Many subepithelial infiltrating cells are immunostained. (G) Anti-HLA-DR. Basal cells of conjunctival epithelium, subepithelial infiltrating cells, and endothelial cells of blood vessels are immunostained. (H) Anti-ICAM-1. Basal cells of conjunctival epithelium, subepithelial infiltrating cells, and endothelial cells of blood vessels are weakly immunostained. (I) Anti-IFN-γ. Basal cells of conjunctival epithelium, subepithelial infiltrating cells, and endothelial cells of blood vessels are weakly immunoreactive. (J) Anti-IL-4. No positive staining is seen in this section except for some polymorphonuclear cells in the vascular lumen. (K) A negative control section incubated with IgG1 in lieu of a primary antibody. Scale bar (upper right) 100 µm.
we often see patients with Stevens–Johnson syndrome with slowly progressive conjunctivalisation of cornea and decline of visual acuity even when many years have passed after the initial attack. Also, the outcome of keratoplasty for patients with Stevens–Johnson syndrome is very poor compared with other corneal diseases. Before this study, we believed that both poor surgical outcome and chronically progressive conjunctivalisation are based on the specific immunopathogenesis of Stevens–Johnson syndrome. To our surprise, substantial inflammatory cell infiltration was observed in the five patients with Stevens–Johnson syndrome. Despite little or no inflammation being noted clinically. In contrast with our preconceptions, the immunopathological features of conjunctivalised corneas in Stevens–Johnson syndrome are not appreciably different from the immunopathological features of those in chemical injury. Also, within the group of five patients examined, the pattern of immunoreactivity to antibodies examined here was fairly consistent and no clear correlation emerged betwen the immunopathological findings of an individual patient and the patients’ clinical histories (Table 1). Our results revealed that inflammatory cells in the substantia propria of conjunctivalised corneas of patients with Stevens–Johnson syndrome are composed of CD4 positive T cells, CD8 positive T cells, and/or macrophages. B lymphocytes are probably not present. In addition to this, we tried to identify CD4 positive T cells from the cytokine expression pattern. Our results revealed the predominance of IFN-γ suggesting that CD4 positive T cells were mainly Th1 cells that can promote cellular immunity.9

Interestingly, Foster and associates, in their immunohistochemical study of two patients with Stevens–Johnson syndrome who experienced recurrent episodes of inflammation, found that the predominant T cells in conjunctiva were T helper cells, rather than suppressor T cells which usually outnumber T helper cells in normal conjunctiva.10 These authors also found HLA-DR positive cells in the epithelium and substantia propria of conjunctiva that they identified as Langerhans cells, macrophages, and activated T cells. Though their results are similar to ours, the clinical types of patients they examined are apparently different from ours. However, the difference between patients with Stevens–Johnson syndrome who experience recurrent episodes of conjunctival inflammation and those who don’t is not readily evident.

A similar immunostaining pattern between Stevens–Johnson syndrome and chemical injury corneas suggests that inflammatory cell infiltration in the substantia propria of patients with Stevens–Johnson syndrome may not be a primary reaction but a secondary reaction from other ocular abnormalities related to stem cell failure such as trichiasis or severe dry eye. We feel that these pre-existing infiltrating cells at surgery may play an important part in graft rejection and/or post-surgically induced inflammation in patients with Stevens–Johnson syndrome.

The authors thank Nigel Fullwood, PhD, for critical reviewing of the manuscript.

Supported by grants in aid for scientific research (numbers 09771460, 09B77356, and 08457467) from the Ministry of Education, Culture and Science of Japan, Tokyo, Japan, by the Kyoto Foundation for the Promotion of Medical Science, Kyoto, Japan, and by the Intramural Research Fund of Kyoto Prefectural University of Medicine, Kyoto, Japan.

Table 1  Patient clinical data and results of immunostaining

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>VA</th>
<th>Duration</th>
<th>Inflammation</th>
<th>LFA-1</th>
<th>CD4</th>
<th>CD8</th>
<th>CD19</th>
<th>CD68</th>
<th>HLA-DR</th>
<th>ICAM-1</th>
<th>IFN-γ</th>
<th>IL-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Male</td>
<td>20:40</td>
<td>11 years</td>
<td>Mild</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>61</td>
<td>Male</td>
<td>20:40</td>
<td>25 years</td>
<td>None</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>74</td>
<td>Female</td>
<td>20:40</td>
<td>30 years</td>
<td>Mild</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>27</td>
<td>Male</td>
<td>20:40</td>
<td>20 years</td>
<td>Mild</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>25</td>
<td>Male</td>
<td>20:40</td>
<td>3 years</td>
<td>None</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Age = age at surgery.
VA = visual acuity at the time of surgery.
Duration = duration from the initial attack to surgery.
Inflammation = clinical inflammation at the time of surgery.
+ = immunoreactive.
− = not immunoreactive, apart from some immunoreactive polymorphonuclear cells in vascular lumen.
SI = subepithelial infiltrating cells.
CCE = conjunctivalised corneal epithelial cells.
EV = endothelial cells of blood vessel.


www.bjophthalmol.com
Conjunctival inflammation in the chronic phase of Stevens–Johnson syndrome

Satoshi Kawasaki, Kohji Nishida, Chie Sotozono, Andrew J Quantock and Shigeru Kinoshita

*Br J Ophthalmol* 2000 84: 1191-1193
doi: 10.1136/bjo.84.10.1191

Updated information and services can be found at:
http://bjo.bmj.com/content/84/10/1191

These include:

**References**
This article cites 8 articles, 1 of which you can access for free at:
http://bjo.bmj.com/content/84/10/1191#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/